Osimertinib (TAGRISSO)
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor
Osimertinib (TAGRISSO)
Forms and strengths
Form: TabletStrength: 40 mg, 80 mg
References
Indication
- Osimertinib is used as adjuvant therapy after tumour removal in patients with early-stage (IB-IIIA) non-small cell lung cancer (NSCLC) whose tumours have EGFR exon 19 deletion or exon 21 (L858R) mutations.
- Osimertinib is used to treat locally advanced, unresectable (stage III) EGFR mutation-positive NSCLC that has not progressed after platinum-based chemoradiation therapy.
- Osimertinib is used as first-line treatment, alone or combined with pemetrexed and platinum-based chemotherapy, for locally advanced or metastatic EGFR mutation-positive NSCLC.
- Osimertinib is used to treat locally advanced or metastatic NSCLC with the EGFR T790M mutation that has progressed after previous EGFR tyrosine kinase inhibitor therapy.
- A validated laboratory test confirming EGFR mutation status is required before starting osimertinib for any indication.
Pregnancy
- Osimertinib may cause fetal harm; animal studies showed embryo-fetal death, reduced fetal growth, and neonatal death at exposures similar to those expected in humans.
- Osimertinib should not be used during pregnancy unless clearly necessary, after weighing the risk to the fetus against the benefit to the mother.
- Women of childbearing potential should avoid becoming pregnant during treatment and for at least 2 months after the final dose.
- Male patients with partners of childbearing potential should use contraception during treatment and for at least 4 months after the final dose.
Breastfeeding
- It is not known whether osimertinib or its metabolites pass into human breast milk.
- Breastfeeding should be discontinued during treatment with osimertinib, given the potential risk to a nursing infant.
Geriatrics
- No dose adjustment is required based on age; however, older patients reported more Grade 3 or higher side effects and more dose interruptions or reductions than younger patients.
Pediatrics
- Osimertinib is not authorized for use in children under 18 years of age, as no data are available to Health Canada.
Dosage & Administration
- The recommended dose is one 80 mg tablet taken orally once daily, with or without food, at the same time each day.
- In the adjuvant setting, treatment is continued for up to 3 years or until disease recurrence or unacceptable toxicity.
- For locally advanced or metastatic disease, treatment continues until disease progression or unacceptable toxicity.
- If a dose needs to be reduced for tolerability, the dose is lowered to 40 mg once daily.
- If a strong CYP3A4 inducer must be used concomitantly, the dose is increased to 160 mg daily during co-administration and for 3 weeks after the inducer is stopped, then resumed at 80 mg daily.
- No dose adjustment is required for mild to moderate hepatic or mild to severe renal impairment; caution is advised in severe or end-stage renal impairment, and the appropriate dose in severe hepatic impairment has not been established.
- If a dose is missed, it can be made up unless the next scheduled dose is due within 12 hours.
- Tablets should be swallowed whole; if a patient cannot swallow the tablet, it can be dispersed in non-carbonated water and taken immediately, without crushing or chewing.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Doses up to three times the standard dose have been tested in clinical trials without dose-limiting toxicity.
- Higher-than-recommended doses were associated with an increased frequency and severity of typical EGFR-inhibitor effects, mainly diarrhea and skin rash.
- There is no specific antidote; treatment is symptomatic and supportive, including ECG monitoring.
Common side effects
- Diarrhea is very common.
- Rash is very common.
- Paronychia (nail-fold inflammation) is very common.
- Dry skin is very common.
- Stomatitis (mouth sores) is very common.
- Itching (pruritus) is common.
- Decreased platelet count is common.
- Decreased white blood cell count is common.
- Decreased neutrophil count is common.
- Nosebleeds (epistaxis) may occur.
- Decreased appetite may occur.
- Fatigue may occur.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Interstitial lung disease (including pneumonitis), sometimes fatal, may occur and requires prompt evaluation of any new or worsening cough, shortness of breath, or fever.
- QT interval prolongation may occur and can increase the risk of dangerous heart rhythm disturbances.
- Heart failure and reduced heart pumping function (decreased left ventricular ejection fraction) may occur.
- Rare cases of aplastic anemia have been reported, some fatal; watch for persistent fever, bruising, bleeding, or unusual paleness.
- Keratitis (eye inflammation) may occur; contact lens users are at additional risk and should be referred promptly to an eye specialist if symptoms develop.
- Severe skin reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis, have been reported rarely.
- Erythema multiforme has been reported uncommonly.
- Muscle breakdown (rhabdomyolysis) and muscle inflammation (myositis) have been reported.
- Radiation pneumonitis may occur, particularly following prior chemoradiation therapy.
- Seek urgent medical attention for new or worsening breathing problems, chest pain or palpitations, severe skin blistering or peeling, persistent fever, or unusual bruising or bleeding.
Use with caution
- Use with caution in patients with cardiac risk factors, and consider baseline and periodic heart function (LVEF) monitoring.
- Use with caution in patients with a history of long QT syndrome, and obtain ECGs before starting and periodically during treatment.
- Correct low potassium, calcium, or magnesium levels before starting treatment.
- Use with caution in patients with a history of interstitial lung disease or radiation pneumonitis requiring steroids.
- Use with caution in patients with pre-existing liver disease; the appropriate dose has not been established for severe hepatic impairment.
- Use with caution in patients with severe or end-stage kidney disease, or those on dialysis, since safety has not been established.
- Use sun protection and monitor for suspicious skin changes, since skin reactions are common with this drug.
- Use moisturizers regularly and keep hands clean and dry to help prevent or manage paronychia.
Contraindications
- Contraindicated in patients with known hypersensitivity to osimertinib or to any ingredient in the formulation, including any non-medicinal ingredient or component of the container.
Drug interactions
- Strong CYP3A4 inducers, such as rifampicin, phenytoin, carbamazepine, and St. John's Wort, decrease osimertinib levels and should be avoided; if unavoidable, the osimertinib dose should be increased.
- Osimertinib increases exposure to drugs that rely on BCRP transport, such as rosuvastatin; monitor for increased side effects of these medications.
- Osimertinib increases exposure to P-glycoprotein substrates with a narrow therapeutic index, such as digoxin, dabigatran, and aliskiren; monitor for increased side effects.
- Strong CYP3A4/5 inhibitors, such as itraconazole, are not expected to meaningfully change osimertinib levels.
- Osimertinib may cause small reductions in the levels of some CYP3A4 substrates, such as simvastatin, though this is not usually clinically significant.
- Concomitant use with other QT-prolonging drugs should be avoided when possible, or used with caution and closer ECG monitoring.
Food interactions
- Food does not meaningfully change the absorption of osimertinib, so it can be taken with or without food.
Time of administration
- Take once daily at the same time each day, with or without food.
Storage
- Store at controlled room temperature (15°C to 30°C).
- Keep out of the reach of children.
Patient take-away
- Osimertinib is a once-daily targeted tablet for EGFR-mutation-positive lung cancer, taken at the same time each day with or without food.
- Diarrhea, rash, dry skin, and nail-fold irritation are common; contact your care team if these become severe or bothersome.
- Report new or worsening cough, shortness of breath, or fever right away, since rare but serious lung inflammation can occur.
- Regular heart monitoring (ECG) and blood tests are part of routine care during treatment; avoid becoming pregnant while taking osimertinib and for months afterward.